Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets

Published
30 Mar 25
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$5.00
63.4% undervalued intrinsic discount
20 Aug
US$1.83
Loading
1Y
34.1%
7D
-5.4%

Author's Valuation

US$5.0

63.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 7.76%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 59.8x to 66.6x.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 7.20%

AnalystConsensusTarget has decreased revenue growth from -8.8% to -12.2%, increased profit margin from 10.5% to 19.3% and decreased future PE multiple from 102.9x to 59.5x.